The current PE ratio of RGEN can't be determined, as the TTM EPS of -$0.14 is negative. The last recorded PE ratio for Repligen was 741.53 in June 2024.
The average historical PE ratio of Repligen for the last ten years is 141.89. Over the past ten years, RGEN's PE ratio was at its highest in the Jun 2024 quarter at 741.53, when the stock price was $126.06 and the EPS was $0.17. The lowest value was in the Mar 2018 quarter, when it reached 48.89 with a price of $36.18 and an EPS of $0.74.
Maximum annual increase: 455.88% in 2023
Maximum annual decrease: -55.54% in 2022
Year | PE ratio | Change |
---|---|---|
2023 | 280.94 | 455.88% |
2022 | 50.54 | -55.54% |
2021 | 113.67 | -32.38% |
2020 | 168.1 | -20.04% |
2019 | 210.23 | 51.47% |
2018 | 138.79 | 183.07% |
2017 | 49.03 | -44.32% |
2016 | 88.06 | -12.85% |
2015 | 101.04 | 27.58% |
2014 | 79.2 | 196.07% |
Stock name | PE ratio | Market cap |
---|---|---|
CRL Charles River Laboratories International Inc | 23.08 | $9.5B |
GE General Electric Co | 29.33 | $182.23B |
TMO Thermo Fisher Scientific Inc | 32.77 | $200.45B |
PFE Pfizer Inc | 34.68 | $149.38B |
NBIX Neurocrine Biosciences Inc | 35.08 | $13.71B |
BMRN Biomarin Pharmaceutical Inc | 38.62 | $12.51B |
TECH BIO-TECHNE Corp | 77.02 | $11.63B |
NVAX Novavax Inc | N/A | $1.39B |
BMY Bristol Myers Squibb Co | N/A | $116.28B |
SGMO Sangamo Therapeutics Inc | N/A | $515.36M |
RGEN Repligen Corp | N/A | $8.09B |
The current price to earnings ratio of RGEN can't be calculated, as its EPS of -$0.14 is negative.
Over the last 3 years, the average price to earnings ratio for RGEN stock is 183.27.
Over the last 5 years, the average price to earnings ratio for RGEN stock is 177.4.
Over the last ten years, the quarterly PE ratio reached a historic high of 741.53 in the Jun 2024 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.